GlassScriptPhysician profile
Karam Wehbeh
NPI 1306356365
$7,417.90
in general payments reported to CMS, 2019-2025
35 companies · $2,007 in 2025
The $2,007 reported for 2025 was more than what 96% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $330 · 2022: $1,637 · 2023: $1,647 · 2024: $1,797 · 2025: $2,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,432 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,432.45 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,225.67 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,109.93 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $888.29 | 2022-2025 | |
| Amgen INC. | $742.85 | 2021-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $658.16 | 2022-2025 | |
| Pfizer INC. | $339.59 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $285.12 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.17 | 2021-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $240.51 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Exact Sciences Corporation | $218.92 | 2024-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $148.07 | 2024-2025 | Veozah |
| Axsome Therapeutics, INC. | $146.32 | 2023-2025 | Auvelity |
| Kowa Pharmaceuticals America, INC. | $143.87 | 2022-2025 | Zoryve, Livalo |
| Amarin Pharma, INC. | $131.43 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $116.42 | 2022-2025 | Spravato |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $115.28 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $87.32 | 2022-2024 | Freestyle Libre 3 |
| Teva Pharmaceuticals USA, INC. | $80.74 | 2023-2025 | Austedo Xr |
| Merck Sharp & Dohme LLC | $77.61 | 2022-2023 | Steglatro, Belsomra, Verquvo |
| Takeda Pharmaceuticals U.S.A., INC. | $47.91 | 2022-2023 | Vpriv, Trintellix |
| Idorsia Pharmaceuticals US INC | $44.41 | 2022-2024 | Quviviq |
| Corcept Therapeutics | $43.96 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.54 | 2025 | Caplyta |
| Xeris Pharmaceuticals, INC. | $30.75 | 2023 | Gvoke Hypopen |
| Sanofi-Aventis U.S. LLC | $30.22 | 2023 | |
| Esperion Therapeutics, INC. | $29.15 | 2023-2024 | Nexletol |
| Nestle Healthcare Nutrition INC. | $29.08 | 2022 | |
| Neurocrine Biosciences, INC. | $19.34 | 2024 | Ingrezza |
| Eisai INC. | $16.46 | 2023 | |
| Currax Pharmaceuticals LLC | $14.60 | 2023 | Onzetra Xsail, Contrave |
| E.R. Squibb & Sons, L.L.C. | $14.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.84 | 2023 | |
| Ibsa Pharma INC. | $13.79 | 2024 | Licart, Tirosint |
| Paratek Pharmaceuticals, INC. | $13.75 | 2022 | |
| Kaleo, INC. | $12.48 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karam Wehbeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.